Literature DB >> 23724527

Liquid based cytology and HPV DNA testing in a Greek population compared to colposcopy and histology.

S Diamantopoulou1, A Spathis, A Chranioti, D Anninos, M Stamataki, C Chrelias, A Pappas, I Panayiotides, P Karakitsos.   

Abstract

Screening for cervical cancer in Greece is still unorganised and based on self- motivation. The purpose of this study was to evaluate the accuracy of cytological findings from a large observational population sample, originating from Western Athens, in association with reflex DNA test, colposcopic estimation, and final histologic diagnosis. The rate of invasive carcinoma, both squamous cell and adenocarcinoma, is indicative of a largely unscreened population. In this study, the estimated overall prevalence of human papilloma virus (HPV) was 41.1%, with HPV positivity at 37.4% of cytologically normal women. HPV testing did not seem to improve sensitivity of cytology for atypical squamous cells of undetermined significance (ASC-US) and low-grade squamous intraepithelial lesion (LGSIL) cases in identifying CIN 2+ lesions, but outperformed cytology in detecting CIN3+ for cytological high-grade squamous intraepithelial lesion (HGSIL) cases. For HGSIL cases sensitivity of colposcopy for detecting CIN3+ was comparable to cytology.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23724527

Source DB:  PubMed          Journal:  Clin Exp Obstet Gynecol        ISSN: 0390-6663            Impact factor:   0.146


  2 in total

Review 1.  Human papillomavirus infection by anatomical site among Greek men and women: a systematic review.

Authors:  Savas Tsikis; Lea Hoefer; Angella Charnot-Katsikas; John A Schneider
Journal:  Eur J Cancer Prev       Date:  2016-11       Impact factor: 2.497

2.  Association between micronucleus frequency and cervical intraepithelial neoplasia grade in Thinprep cytological test and its significance.

Authors:  Yong-Hua Shi; Bo-Wei Wang; Talaf Tuokan; Qiao-Zhi Li; Ya-Jing Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.